338453-16-0

Basic information

• Product Name: CYCLOBUTANESULFONYL CHLORIDE
• Synonyms: CYCLOBUTANESULFONYL CHLORIDE;Cyclobutyl sulfonyl chloride
• CAS NO: 338453-16-0
• Molecular Formula: C₄H₇ClO₂S
• Molecular Weight: 154.62
• Mol File: 338453-16-0.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 217℃
• Flash Point: 85℃
• Appearance: /
• Density: 1.42
• Refractive Index: 1.4603
• CAS DataBase Reference: CYCLOBUTANESULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: CYCLOBUTANESULFONYL CHLORIDE(338453-16-0)
• EPA Substance Registry System: CYCLOBUTANESULFONYL CHLORIDE(338453-16-0)

Safety Data

• Hazardous Substances Data: 338453-16-0(Hazardous Substances Data)

Usage

Uses

Cyclobutanesulfonyl Chloride is used in the development of a chemical toolset for studying the paralog-specific function of IRE1.

Upstream product

• 7791-25-5 sulfuryl dichloride 
• 72507-51-8 cyclobutyllithium 
• 338457-55-9 potassium cyclobutane-sulphonate 
• 287-23-0 cyclobutane 
• 4399-47-7 Bromocyclobutane 

Downstream Products

• 445305-91-9 cyclobutyl sulfonamide 
• 338457-54-8 cyclobutane-sulphonic acid 5-(2,4-diamino-pyrimidin-5-ylmethyl)-3-ethoxy-2-iodo-phenyl ester 
• 1283126-32-8 ethyl 6-(2-(tert-butoxycarbonyl-((R)-2-(3-(cyclobutanesulfonamide)phenyl)-2-(triethylsilyloxy)ethyl)amino)ethoxy)-1-(tetrahydro-2H-pyran-2-yl)indazole-3-carboxylate 
• 1436387-73-3 tert-butyl 1-benzyl-7-(cyclobutanesulfonamidomethyl)-1,2,3,4-tetrahydronaphthalen-2-ylcarbamate 
• 1295567-54-2 N-(2-{3-[(ethylsulfonyl)amino]phenoxy}-4-fluoro-6-[(2-fluoro-4-iodophenyl)amino]phenyl)cyclobutanesulfonamide 

Relevant articles and documents

REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS

The present disclosure provides compounds of Formula IA and Formula IB and their pharmaceutical compositions as selective agonists of REV-ERB-α: where R1, R2, R3, R4, R5, RX1, RX2, nA, nB, X, Y, and Z are described herein. The compounds are useful in various methods and uses, such as in the treatment of diseases including hyperglycemia, dyslipidemia, atherosclerosis, and autoimmune and inflammatory disorders or diseases, and as cancer therapeutics, such as for the treatment of glioblastoma, hepatocellular carcinoma, and colorectal cancer, and for immune-oncology purposes.

INDAZOLE ANALOGUE

[Objective] To provide a drug that selectively stimulates the β3-adrenergic receptors, particularly a drug capable of preferentially stimulating the β3-adrenergic receptors over the α1-adrenergic receptors. This drug can be used in the treatment and prevention of diabetes, obesity, hyperlipidemia, depression, cholelithiasis, diseases caused by biliary hyperkinesia, diseases caused by hyperfunction of the gastrointestinal tract, interstitial cystitis, overactive bladder or urinary incontinence, diseases associated with decreased lacrimation, and the like. [Solution] Indazole analogs represented by the general formula (I) or a salt thereof. Drugs that contains these indazole analogs or a salt thereof as the active ingredient.

CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS

The invention encompasses compounds of formula (I) as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV